https://www.selleckchem.com/pr....oducts/semaxanib-su5
44 ± 0.93 μm, = 0.009) thicknesses were also lower in AQP4-nonON compared to HC eyes. Results were similar in sensitivity analyses restricted to AQP4-IgG+ patients who had never experienced ON in either eye. AQP4-nonON eyes exhibit evidence of subclinical retinal ganglion cell neuronal and axonal loss, as well as structural evidence of photoreceptor layer involvement. These findings support that subclinical anterior visual pathway involvement may occur in AQP4-IgG+ NMOSD. AQP4-nonON eyes exhibit evidence of subclinical retinal
Like
Comment
Share
